Skip to content
value.today

Cell Biosciences Inc.

Total raised
$20 M
2 rounds on record
Latest round
$15 M
Oct 2009
First round on record
Apr 2009
Today
Private
No later event on record

Funding rounds

2 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Cell Biosciences Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2011$13 MIssued in a merger or acquisition$10 to $50 million

Cell Biosciences Inc.: Private sale, May 2011

Investors in this round

14 investors had bought by the notice of May 23, 2011: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$13 M of $13 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: "Offering of Series F Preferred Stock (""Series F""), warrants to purchase Common Stock (""Warrants"") and the underlying shares of Common Stock isuable upon conversion of the Series F and upon exerci
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jason Blaine Novi · Executive Officer
  • Timothy Harkness · Executive Officer, Director
  • A. Blaine Bowman · Director
  • David Barker · Director
  • Jack Blaine Nielson · Director
  • James Blaine Woody · Director
  • Ron Blaine Eastman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “The Issuer used approximately $9,000,000 of the total amount sold in the offering to purchase all of the outstanding shares of Brightwell Technologies, Inc.”

Signed by Timothy Harkness, President and CEO. Source: SEC Form D, newest notice filed May 23, 2011. Read the notice at the SEC.

equity, optionsSEC
Oct 2010$20 MIssued in a merger or acquisition$10 to $50 million

Cell Biosciences Inc.: Private sale, Oct 2010

Investors in this round

14 investors had bought by the notice of Nov 1, 2010: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$20 M of $21 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: "Offering of Series F Preferred Stock (""Series F""), warrants to purchase Common Stock (""Warrants"") and the underlying shares of Common Stock isuable upon conversion of the Series F and upon exerci
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jason Blaine Novi · Executive Officer
  • Timothy Harkness · Executive Officer, Director
  • A. Blaine Bowman · Director
  • David Barker · Director
  • Jack Blaine Nielson · Director
  • James Blaine Woody · Director
  • James Blair · Director
  • Ron Blaine Eastman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “The Issuer used approximately $12.3M of the total amount sold to purchase all of the outstanding shares of Convergent Bioscience Ltd. and $700,000 of the total amount sold to purchase all of the oustanding shares of Convergent Bioscience Services, Inc.”

Signed by Timothy Harkness, President and CEO. Source: SEC Form D, newest notice filed Nov 1, 2010. Read the notice at the SEC.

equitySEC
Dec 2009$9 MIssued in a merger or acquisition$2 to $10 million

Cell Biosciences Inc.: Private sale, Dec 2009

Investors in this round

3 investors had bought by the notice of Dec 21, 2009: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $10 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: "Offering of Series E Preferred Stock (""Series E""), and the underlying shares of Common Stock isuable upon conversion of the Series E."
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jason Blaine Novi · Executive Officer
  • Timothy Harkness · Executive Officer, Director
  • A. Blaine Bowman · Director
  • David Barker · Director
  • Jack Blaine Nielson · Director
  • James Blaine Woody · Director
  • James Blair · Director
  • Julie Blaine Eskay-Eagle · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “$5,250,000 of the Issuer's Series E was issued in exchange for outstanding senior notes of target company and $3,999,999 of the Issuer's Series E was issued in connection with a venture capital financing.”

Signed by Timothy Harkness, President and CEO. Source: SEC Form D, newest notice filed Dec 21, 2009. Read the notice at the SEC.

equitySEC
Oct 2009$15 MNo. 2$10 to $50 million

Cell Biosciences Inc.: Raise no. 2, Oct 2009

Investors in this round

10 investors had bought by the notice of Nov 12, 2009: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $18 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: "Offering of Series D Preferred Stock (the ""Series D""), warrants to purchase Common Stock (the ""Warrants"") and the underlying shares of Common Stock issuable upon exercise of Warrants and upon con
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James Blaine Novi · Executive Officer
  • Timothy Harkness · Executive Officer, Director
  • A. Blaine Bowman · Director
  • David Barker · Director
  • Jack Blaine Nielson · Director
  • James Blaine Woody · Director
  • James Blair · Director
  • Julie Blaine Eskay-Eagle · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes the aggregate exercise price of Warrants (as defined in Item 9)”

Signed by Timothy Harkness, President and CEO. Source: SEC Form D, newest notice filed Nov 12, 2009. Read the notice at the SEC.

equity, optionsSEC
Apr 2009$5 MNo. 1$2 to $10 million

Cell Biosciences Inc.: Raise no. 1, Apr 2009

Investors in this round

11 investors had bought by the notice of Apr 20, 2009: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $11 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: "Offering of Series C Preferred Stock (the ""Series C"") and the underlying shares of Common Stock issuable upon conversion of the Series C."
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in De

People named in the notice

  • James Novi · Executive Officer
  • Timothy Harkness · Executive Officer, Director
  • A. Blaine Bowman · Director
  • David Barker · Director
  • Jack Nielson · Director
  • James Blair · Director
  • James Woody · Director
  • Julie Eskay-Eagle · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Timothy Harkness, President and CEO. Source: SEC Form D, newest notice filed Apr 20, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Cell Biosciences Inc. chose not to state its revenue in its newest notice of a funding round (May 2011).

    SEC Form D · May 2011

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2011

That is all the official record says: Cell Biosciences Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Cell Biosciences Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 11 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cell Biosciences Inc.
NameRoleNamed in
Jason Blaine NoviExecutive officerMay 2011
Timothy HarknessExecutive officerMay 2011
James Blaine NoviExecutive officerNov 2009
James NoviExecutive officerApr 2009
A. Blaine BowmanDirectorMay 2011
David BarkerDirectorMay 2011
Jack Blaine NielsonDirectorMay 2011
James Blaine WoodyDirectorMay 2011
Ron Blaine EastmanDirectorMay 2011
Timothy HarknessDirectorMay 2011
James BlairDirectorNov 2010
Julie Blaine Eskay-EagleDirectorDec 2009
Jack NielsonDirectorApr 2009
James WoodyDirectorApr 2009
Julie Eskay-EagleDirectorApr 2009